Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Coronavirus vaccine(2019-nCoV vaccine)

Trial Profile

A clinical trial of Coronavirus vaccine(2019-nCoV vaccine)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2020

At a glance

  • Drugs Coronavirus vaccine Codagenix (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Feb 2020 New trial record
    • 19 Feb 2020 According to an Serum Institute of India media release, the company expects to be ready with a vaccine against the novel coronavirus (COVID-19) by early 2022. It is expected to progress to human trial phase within the next six months.

Trial Overview

Purpose

This study will evaluate Coronavirus vaccine(2019-nCoV vaccine).

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention -

Subjects

  • Subject Type volunteers
  • Sex male & female

Trial Details

Organisations

  • Affiliations Codagenix; Serum Institute of India

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
Coronavirus vaccine CodagenixPrimary Drug
-
-

Coronavirus vaccine

Trial History

Event Date Event Type Comment
27 Feb 2020 New trial record New trial record Updated 27 Feb 2020
19 Feb 2020 Other trial event According to an Serum Institute of India media release, the company expects to be ready with a vaccine against the novel coronavirus (COVID-19) by early 2022. It is expected to progress to human trial phase within the next six months. Updated 27 Feb 2020

References

  1. Serum Institute of India. Serum Institute to be ready with coronavirus vaccine by 2022 . Media-Rel 2020;.

    Media Release
Back to top